The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104)

• Published in: Journal of thoracic oncology Vol. 14; no. 3; pp. 503 - 512
• Main Authors: Xu, Song-Tao, Xi, Jun-Jie, Zhong, Wen-Zhao, Mao, Wei-Min, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Yang, Xue-Ning, Zhang, Yong-Xing, Yin, Jia-Cheng, Wang, Qun, Wu, Yi-Long
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2019; Copyright by the International Association for the Study of Lung Cancer
• Subjects: adjuvant chemotherapy; Adolescent; Adult; Aged; Antineoplastic Agents - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - secondary; Chemotherapy, Adjuvant - adverse effects; China - epidemiology; EGFR; Female; Follow-Up Studies; gefitinib; Gefitinib - adverse effects; Humans; Incidence; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - pathology; NSCLC; Spatio-Temporal Analysis; Survival Rate; Treatment Failure; tyrosine kinase inhibitor; Young Adult; China; adjuvant chemotherapy; gefitinib; tyrosine kinase inhibitor; NSCLC; EGFR

Adjuvant gefitinib therapy prolonged disease-free survival in patients with resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). However, treatment failure patterns after gefitinib therapy are less well characterized. Overall, 222 stage N1–N2, EGFR-mutant NSCLC patie...